Topic 2 — What Is Engineered TCR-T Therapy?

“Advancing Melanoma Care: Early Identification, Timely Action, and Next-Generation Therapy,” is an educational video series focusing on earlier identification of advanced melanoma, routine HLA-A*02:01 testing, and timely referral to IMA203 (anzu-cel) trial sites. In Topic 2, “What Is Engineered TCR-T Therapy?,” Alison Betof, MD, PhD, FASCO—Director, Melanoma Program, Mark and Mary Stevens Endowed Scholar in Melanoma, and Director, Solid Tumor Cellular Therapy at Stanford University School of Medicine—discusses how engineered TCR-T therapy introduces a level of precision that allows targeting of intracellular tumor antigens — capabilities that checkpoints, CAR-T, or TIL therapy cannot offer. Topics in this brief educational video include how checkpoint inhibitors, TIL therapy, and CAR-T differ in their mechanisms and the unmet needs in melanoma treatment that TCR-T therapy aims to address. Watch the second segment of the series to gain insight into what makes engineered TCR-T therapy fundamentally different.